Despite advances, several challenges persist in optimizing cancer treatment regimens. These include drug resistance, the heterogeneity of tumors, and the diverse responses among patients. Additionally, the high cost of new treatments and the complexity of integrating them into existing regimens can be barriers. Addressing these challenges requires ongoing research, clinical trials, and collaboration between researchers, clinicians, and patients.
